Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1999-12-07
2000-10-31
Johnson, Nancy A.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241841, 4242341, 4242391, 4242471, 514 2, A61K 3900, A61K 3902, A61K 3908
Patent
active
061398454
ABSTRACT:
A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic s adrenal medulla, by direct, local administration of a neurotoxin, such as a botulinum toxin.
REFERENCES:
Bagshawe, K.D., et al.; Antibody Directed Enzyme Prodrug Therapy (Adept): Clinical Report; Disease Markers; vol. 9:233-238 (1991).
Bagshawe, K.D., et al.; A Cytotoxic Agent can be Generated Selectively at Cancer Sites; Br. J. Cancer; 58:700-703 (1988).
Bryan, M.; Glomus Tumors; Dept. of Otolaryngology, UTMB;.sub.-- 10 pages (Jan. 11, 1995).
Eccles, S.A., et al.; Regression of Established Breast Carcinoma Xenografts with Antibody-Directed Enzyme Prodrug Therapy Against c-erbB2 p185; Cancer Research; 54:5171-5177 (Oct. 1, 1994).
Heppner, F.; New Technologies to Combat Malignant Tumours of the Brain; Anticancer Research; 2:101-110 (1982).
Jankovic, J., et al., editors; Therapy with Botulinum Toxin; Marcel Dekker, Inc. publisher; p. 45 (1994).
Lemmon, J.J., et al.; Anaerobic Bacteria as a Gene Delivery System to Tumors; Proceedings of the American Association for Cancer Research; vol. 35:374 (Mar. 1994).
Springer, C.J., et al; Ablation of Human Choriocarcinoma Xenografts in Nude Mice by Antibody-Directed Enzyme Prodrug Therapy (ADEPT) with Three Novel Compounds; Eur J Cancer; 27(11):1361-1366 (1991).
Xu, T., et al.; Kinetic Studies of Ca2+ Binding and Ca2+ Clearance in the Cytosol of Adrenal Chromaffin Cells; Biophysical Journal; vol. 73:532-535 (Jul. 1997).
Minton et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiology Reviews 17:357-364, 1995.
Heppner, F. New technologies to combat malignant tumours of the brain. Anticancer Res. 2(1-2):101-9, 1982.
Johnson and Goldin. The clinical impact of screening and other experimental tumor studies. Cancer Treatment Reviews 2:1-31, 1975.
Heppner and Mose. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir. 42(1-2):123-5, 1978.
Xu et al. Multiple kinetic components of exocytosis distinguished by neurotoxin sensitivity. Nature Neuroscience 1(3):192-200, 1998.
Bigalke, H., et al.; Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture; Brain Research, 360 (1985); 318-324.
Bigalke, H., et al.; Tetanus Toxin and Botulinum A. Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord; Naunyn-Schmiedeberg's Arch. Pharmacol (1981); 316:244-251.
Col, V., et al.; Heart Failure Induced by Pheochromocytoma: Laparoscopic Treatment and Intraoperative Changes of Several New Cardiovascular Hormones; Hormone Research (1999); 51:50-52.
Habermann, E., et al.; Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain; Journal of Neurochemistry; vol. 51; No. 2 (1988); 522-527.
John, H., et al.; Pheochromocytomas: Can Malignant Potential be Predicted?; Urology (1999); 53(4):679-683.
Laskawi, R., et al.; Up-to-Date Report of Botulinum Toxin Type A Treatment in Patients with Gustatory Sweating (Frey's Syndrome); Laryngoscope; (Mar. 1998); 108:381-384.
Lin, J.C., et al.; Cardiac Pheochromocytoma: Resection After Diagnosis by 111-Indium Octreotide Scan; Ann Thorac Surg (1999); 67:555-558.
Naumann, M., et al.; Botulinum Toxin in the Treatment of Neurological Disorders of the Autonomic Nervous System; Arch Neurol (Aug. 1999); 56:914-916.
Ragona, R.M., et al.; Management of Parotid Sialocele with Botulinum Toxin; Laryngoscope; (Aug. 1999); 109: 1344-1346.
Sanchez-Prieto, J., et al.; Botulinum Toxin A Blocks Glutamate Exocytosis from Guinea-Pig Cerebral Cortical Synaptosomes; Eur. J. Biochem. (1987); 165:675-681.
Schweitzer, E.S., et al.; Inhibition of Regulated Catecholamine Secretion from PC12 Cells by the Ca.sup.2+ /Calmodulin Kinase II Inhibitor KN-62; Journal of Cell Science; (1995); 108:2619-2628.
Sigma; Biochemicals and Reagents for Life Science Research; p. 187-188.
Walther, M.M., et al.; Pheochromocytoma: Evaluation, Diagnosis, and Treatment; World J Urol (1999); 17:35-39.
Warwar, R.E., et al.; Coexistence of 3 Tumors of Neural Crest Origin; Arch Ophthalmol (Sep. 1998); 116:1241-1243.
Williamson, L.C., et al.; Clostridial Neurotoxins and Substrate Proteolysis in Intact Neurons; The Journal of Biological Chemistry (Mar. 29, 1996); vol. 271, No. 13; pp. 7694-7699.
Allergan Sales Inc.
Baran Robert J.
Fisher Carlos A.
Harris Alana M.
Johnson Nancy A.
LandOfFree
Method for treating cancer with a neurotoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cancer with a neurotoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cancer with a neurotoxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2048047